Indaptus Therapeutics (INDP) Share-based Compensation (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Share-based Compensation of $227180.0 for Q1 2026, down 5.69% year-over-year from $240891.0 in Q1 2025, and up 50.84% quarter-over-quarter from $150614.0 in Q3 2025.
Indaptus Therapeutics (INDP) Share-based Compensation (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $227180.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 5.69% year-over-year to $227180.0; the TTM figure through Mar 2026 stood at $922807.0 (down 47.92% YoY), while the FY2024 annual figure was $2.3 million, down 22.26% from the prior year.
- Share-based Compensation for Q1 2026 stood at $227180.0, up from $150614.0 in the prior quarter.
- The five-year high for Share-based Compensation was $904395.0 in Q2 2022, with the low at $150614.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $682387.0 (2022), against an average of $590482.6.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 4274.76% in 2022, then tumbled 68.9% in 2025.
- Indaptus Therapeutics' Share-based Compensation stood at $637630.0 in 2022, then advanced by 16.92% to $745525.0 in 2023, then slumped by 59.21% to $304122.0 in 2024, then sank by 50.48% to $150614.0 in 2025, then surged by 50.84% to $227180.0 in 2026.
- Business Quant data shows INDP's Share-based Compensation at $227180.0 in Q1 2026, $150614.0 in Q3 2025, and $600000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Indaptus Therapeutics | 145.16 Mn | 133.61 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 227,180.00 |
| Mar 31, 2026 | 227,180.00 |
| Sep 30, 2025 | 150,614.00 |
| Sep 30, 2025 | 150,614.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 240,891.00 |
| Mar 31, 2025 | 240,891.00 |
| Dec 31, 2024 | 304,122.00 |
| Dec 31, 2024 | 304,122.00 |
| Sep 30, 2024 | 444,184.00 |
| Sep 30, 2024 | 444,184.00 |
| Jun 30, 2024 | 782,852.00 |
| Jun 30, 2024 | 782,852.00 |
| Mar 31, 2024 | 774,691.00 |
| Mar 31, 2024 | 774,691.00 |
| Dec 31, 2023 | 745,525.00 |
| Dec 31, 2023 | 745,525.00 |